|
|
Neurocrine Biosciences Inc (NBIX) |
|
|
|
| |
NBIX's Net Income Growth by Quarter and Year
Neurocrine Biosciences Inc 's Net Income results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| NBIX Net Income (in millions $) |
FY 2024 |
FY 2023 |
FY 2022 |
FY 2021 |
| IV Quarter |
December |
-
|
147.70
|
89.00
|
72.80
|
| III Quarter |
September |
-
|
83.10
|
68.50
|
42.30
|
| II Quarter |
June |
65.00
|
95.50
|
-16.90
|
32.10
|
| I Quarter |
March |
43.40
|
-76.60
|
13.90
|
-22.39
|
| FY |
|
108.40
|
249.70
|
154.50
|
124.81
|
| NBIX Net Income second quarter 2024 Y/Y Growth Comment |
Neurocrine Biosciences Inc reported fall in Net Income in the second quarter 2024 by -31.94% to $ 65.00 millions, from the same quarter in 2023.
The drop in the second quarter 2024 Neurocrine Biosciences Inc 's Net Income compares unfavorably to the Company's average Net Income increase of 10.32%.
According to the results reported in the second quarter 2024, Neurocrine Biosciences Inc achieved the best Net Income growth in Biotechnology & Pharmaceuticals industry. While Neurocrine Biosciences Inc ' s Net Income drop of -31.94% ranks overall at the positon no. 25 in the second quarter 2024.
|
| NBIX Net Income ( Y/Y Growth %) |
2024
|
2023 |
2022 |
2021 |
| IV Quarter |
December |
- |
65.96 % |
22.25 % |
- |
| III Quarter |
September |
- |
21.31 % |
61.94 % |
-46.86 % |
| II Quarter |
June |
-31.94 % |
- |
- |
-14.17 % |
| I Quarter |
March |
- |
- |
- |
- |
| FY |
|
- |
61.62 % |
23.79 % |
33.63 % |
NBIX Net Income (Quarter on Quarter Growth %) |
2024
|
2023 |
2022 |
2021 |
| IV Quarter |
December |
- |
77.74 % |
29.93 % |
72.1 % |
| III Quarter |
September |
- |
-12.98 % |
- |
31.78 % |
| II Quarter |
June |
49.77 % |
- |
- |
- |
| I Quarter |
March |
-70.62 % |
- |
-80.91 % |
- |
| FY (Year on Year) |
|
- |
61.62 % |
23.79 % |
33.63 % |
| Net Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 1033.62 % |
10.32 % |
-1304.82 % |
| (Jun 30 2020) |
|
(Dec. 30, 2012) |
|
|
| Net Income Y/Y Growth Statistics |
| High |
Average |
Low |
| 1033.62 % |
10.32 % |
-1304.82 % |
| (Jun 30 2020) |
|
(Dec. 30, 2012) |
|
| Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024 |
Neurocrine Biosciences Inc 's Q/Q Net Income Growth
| Net Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 112.83 % |
4.26 % |
-80.91 % |
| (Jun 30 2020) |
|
|
| NBIX's II. Quarter Q/Q Net Income Comment |
Neurocrine Biosciences Inc achieved in the II. Quarter 2024 above company average sequential Net Income jump of 49.77%, to $ 65.00 millions, from $43.40 millions in the first quarter.
NBIX is impressively improving, not only recording higher then regular increase, but also improving pace.
Within Biotechnology & Pharmaceuticals industry Neurocrine Biosciences Inc achieved highest sequential Net Income growth. While Neurocrine Biosciences Inc 's Net Income growth quarter on quarter, overall rank is 104. |
|
|
|
| Net Income Q/Q Growth Statistics |
| High |
Average |
Low |
| 112.83 % |
4.26 % |
-80.91 % |
| (Jun 30 2020) |
|
|
| NBIX's II. Quarter Q/Q Net Income Comment |
Neurocrine Biosciences Inc achieved in the II. Quarter 2024 above company average sequential Net Income jump of 49.77%, to $ 65.00 millions, from $43.40 millions in the first quarter.
Neurocrine Biosciences Inc is undergoing a remarkable growth, not only reporting better then average growth, and also improving speed, Cameron Williams, an industry contributor said.
Within Biotechnology & Pharmaceuticals industry Neurocrine Biosciences Inc achieved highest sequential Net Income growth. While Neurocrine Biosciences Inc 's Net Income growth quarter on quarter, overall rank is 104. |
|
Neurocrine Biosciences Inc 's 12 Months Net Income Growth Year on Year
Net Income TTM Growth |
12 Months Ending
(Jun 30 2024) |
12 Months Ending
(Mar 31 2024) |
12 Months Ending
(Dec 31 2023) |
12 Months Ending
(Sep 30 2023) |
12 Months Ending
(Jun 30 2023) |
| Cumulative Net Income 12 Months Ending |
$ 339.20 |
$ 369.70 |
$ 249.70 |
$ 191.00 |
$ 176.40 |
| Y / Y Net Income Growth (TTM) |
92.29 % |
477.66 % |
61.62 % |
38.11 % |
57.36 % |
| Year on Year Net Income Growth Overall
Ranking |
# 85 |
# 1280 |
# 450 |
# 581 |
# 53 |
| Seqeuential Net Income Change (TTM) |
-8.25 % |
48.06 % |
30.73 % |
8.28 % |
175.63 % |
| Seq. Net Income Growth (TTM) Overall
Ranking |
# 25 |
# 1487 |
# 598 |
# 586 |
# 461 |
| Cumulative Net Income growth
Comment |
Assuming the Neurocrine Biosciences Inc 's fiscal year would have ended in Jun 30 2024, Neurocrine Biosciences Inc would have reprted above average annual Net Income growth of 92.29% year on year, of $ 339 millions.
This marks a slow-down of the companys growth trends and from the 477.66% surge in Mar 31 2024. But still, Neurocrine Biosciences Inc had highest Net Income growth, in Biotechnology & Pharmaceuticals industry.
Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 85, from total ranking in previous quarter at 1280. |
| Net Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
1033.62 % |
10.32 % |
-1304.82 % |
|
|
|
|
|
| Net Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
1033.62 % |
10.32 % |
-1304.82 % |
|
|
|
| Net Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 0 |
| Sector |
# 5 |
| S&P 500 |
# 25 |
|
| Cumulative Net Income growth
Comment |
Assuming the Neurocrine Biosciences Inc 's fiscal year would have ended in Jun 30 2024, Neurocrine Biosciences Inc would have reprted above average annual Net Income growth of 92.29% year on year, of $ 339 millions.
This marks a slow-down of the companys growth trends and from the 477.66% surge in Mar 31 2024. But still, Neurocrine Biosciences Inc had highest Net Income growth, in Biotechnology & Pharmaceuticals industry.
Among companies within the Healthcare sector 7 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 85, from total ranking in previous quarter at 1280. |
| Net Income TTM Q/Q Growth Statistics |
| High |
Average |
Low |
1033.62 % |
10.32 % |
-1304.82 % |
|
|
|
| Net Income TTM Y/Y Growth Statistics |
| High |
Average |
Low |
1033.62 % |
10.32 % |
-1304.82 % |
|
|
|
| Net Income TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 0 |
| Sector |
# 5 |
| S&P 500 |
# 25 |
|
